LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing LOXL2-induced epithelial-mesenchymal transition (EMT)

Explore this paper's citation graph

Summary

LOXL2 may be a promising diagnostic and therapeutic biomarker for cervical cancer, and its small molecule inhibitor may be an effective anti-tumor drug.

Type
article
Published
2022-05-04
Cited by
21
References
58
Access
Open access

Keywords

Lysyl oxidase, Epithelial–mesenchymal transition, Cancer research, Carcinogenesis, Biology

References

Cited by

Related papers